|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 8293 |
FusionGeneSummary for CPQ_KSR2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CPQ_KSR2 | Fusion gene ID: 8293 | Hgene | Tgene | Gene symbol | CPQ | KSR2 | Gene ID | 10404 | 283455 |
| Gene name | carboxypeptidase Q | kinase suppressor of ras 2 | |
| Synonyms | LDP|PGCP | - | |
| Cytomap | 8q22.1 | 12q24.22-q24.23 | |
| Type of gene | protein-coding | protein-coding | |
| Description | carboxypeptidase QSer-Met dipeptidaseaminopeptidaseblood plasma glutamate carboxypeptidaselysosomal dipeptidase | kinase suppressor of Ras 2 | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q9Y646 | Q6VAB6 | |
| Ensembl transtripts involved in fusion gene | ENST00000220763, ENST00000529551, | ENST00000425217, ENST00000339824, ENST00000302438, ENST00000545002, | |
| Fusion gene scores | * DoF score | 8 X 5 X 5=200 | 4 X 3 X 3=36 |
| # samples | 7 | 5 | |
| ** MAII score | log2(7/200*10)=-1.51457317282976 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/36*10)=0.473931188332412 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: CPQ [Title/Abstract] AND KSR2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CPQ | GO:0006508 | proteolysis | 10206990 |
| Hgene | CPQ | GO:0043171 | peptide catabolic process | 10206990 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | SARC | TCGA-3B-A9HO-01A | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5UTR-3CDS | ENST00000220763 | ENST00000425217 | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
| 5UTR-3CDS | ENST00000220763 | ENST00000339824 | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
| 5UTR-intron | ENST00000220763 | ENST00000302438 | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
| 5UTR-intron | ENST00000220763 | ENST00000545002 | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
| intron-3CDS | ENST00000529551 | ENST00000425217 | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
| intron-3CDS | ENST00000529551 | ENST00000339824 | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
| intron-intron | ENST00000529551 | ENST00000302438 | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
| intron-intron | ENST00000529551 | ENST00000545002 | CPQ | chr8 | 97657630 | + | KSR2 | chr12 | 118298236 | - |
Top |
FusionProtFeatures for CPQ_KSR2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CPQ | KSR2 |
| Carboxypeptidase that may play an important role in thehydrolysis of circulating peptides. Catalyzes the hydrolysis ofdipeptides with unsubstituted terminals into amino acids. May playa role in the liberation of thyroxine hormone from itsthyroglobulin (Tg) precursor. | Location-regulated scaffold connecting MEK to RAF. Hasvery low protein kinase activity and can phosphorylate MAP2K1 atseveral Ser and Thr residues with very low efficiency (in vitro).Interaction with BRAF enhances KSR2-mediated phosphorylation ofMAP2K1 (in vitro). Blocks MAP3K8 kinase activity and MAP3K8-mediated signaling. Acts as a negative regulator of MAP3K3-mediated activation of ERK, JNK and NF-kappa-B pathways,inhibiting MAP3K3-mediated interleukin-8 production.{ECO:0000269|PubMed:12975377, ECO:0000269|PubMed:16039990,ECO:0000269|PubMed:21441910}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for CPQ_KSR2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for CPQ_KSR2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| CPQ | KSR2 | MAP2K1, MAP3K8, COPS6, HSP90AA1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for CPQ_KSR2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | CPQ | Q9Y646 | DB00142 | Glutamic Acid | Carboxypeptidase Q | small molecule | approved|nutraceutical |
Top |
RelatedDiseases for CPQ_KSR2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | CPQ | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| Hgene | CPQ | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|